Business
Licence & Supply Agreement with New Partner
Licence & Supply Agreement with New Partner.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Oxford Biomedica signs Licence & Supply Agreement with new partner for LentiVector® platform for late-stage clinical programme\n \n \n \n \n Oxford, UK - 7 September 2022: \n \n Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Company\"), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (\"LSA\") with an undisclosed US-based late-stage cell and gene therapy company. The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica's LentiVector® platform for its application in their lead programme, a cell-based therapy targeting a rare indication, putting into place a five-year clinical supply arrangement.\n \n \n Under the terms of the LSA, Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. The Company will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of drug product sold that utilises Oxford Biomedica's LentiVector® platform.\n \n \n \n \n Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: \"This partnership further demonstrates Oxford Biomedica's world leadership in the delivery of viral vectors for cell and gene therapies and the momentum we are building, with this being the fifth new or expanded customer partnership we have announced this year. We look forward to continuing to build upon our position as a partner of choice to deliver life-saving cell and gene therapies to patients.\"\n \n \n \n \n \n \n \n -Ends-\n \n \n \n \n \n \n \n Enquiries: \n \n \n \n \n Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]\n \n \n Stuart Paynter, Chief Financial Officer\n Sophia Bolhassan, VP, Corporate Affairs & Investor Relations\n \n \n \n \n \n Consilium Strategic Communications:\n \n \n \n \n T: +44 (0)20 3709 5700 / E: [email protected]\n \n \n \n \n \n Mary-Jane Elliott / Matthew Neal / Matthew Cole \n \n \n \n \n \n \n \n About Oxford Biomedica\n \n \n Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focu...